Clinical Trial Update: Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating super-selective intraarterial infusion of cetuximab (Erbitux) for relapsed/refractory glioblastoma and anaplastic astrocytom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Northwell Health | Conditions: Glioblastoma Multiforme (GBM), ANAPLASTIC ASTROCYTOMA (AOA) | Phase 1 | Status: COMPLETED